Topic:

R&D

Latest Headlines

Latest Headlines

KemPharm spikes as its anti-abuse pain drug rolls toward the FDA

KemPharm, at work on an abuse-deterrent formulation of hydrocodone, said its lead drug performed well in a study designed to determine how easily the pill can be ground up and snorted.

Lilly's CEO keeps faith in the pipeline as biotech gets 'too expensive'

Eli Lilly is staking its future on a pair of high-stakes Phase III programs, shying away from any big biotech buyouts as sticker prices continue to soar.

Novo Nordisk ties the R&D knot with Genmab, and they're not focused on cancer

Novo Nordisk is jumping on Genmab's antibody development platform in search of two new drug programs--and this time the Danish biotech company will not be focused on another cancer pact.

Avalanche hits the brakes on its gene therapy program after a Phase II misstep

Avalanche Biotechnologies, months removed from a costly Phase II dud, is calling off plans for further study of its lead gene therapy candidate, heading back to the lab to regroup before trying another clinical trial.

Boehringer takes a neuroscience approach to obesity with latest deal

Boehringer Ingelheim is pairing up with a small California biotech to explore the role circuits in the nervous system play in obesity, scouting for drug targets that could spur weight loss.

Pfizer, OrbiMed back $40M Rhythm round for rare genetic disease R&D

Boston-based Rhythm has gone back to the venture well to draw up a fresh $40 million in backing from some A-list investors to fuel a mid-stage program for rare genetic disorders linked with a lethal level of obesity.

Chorus grows for reform in vaccine development process

As the Ebola outbreak continues to wane in West Africa, vaccines experts are combing over what went wrong--and right--with the development of vaccine candidates against the virus.

UPDATED: Senseonics nabs $10M in venture funding for its implantable blood glucose monitor

Senseonics, the maker of an implantable continuous glucose monitor device, has picked up $20 million in venture funding, according to a regulatory filing.

Novavax reports positive top-line data from PhII trial of RSV vaccine

There is no vaccine for respiratory syncytial virus (RSV), which causes 177,000 hospitalizations and 14,000 deaths each year in adults older than 65. But early data from Novavax's Phase II trial of its RSV candidate show its promise in protecting older adults.

AbbVie, Roche score a pivotal success with their 'breakthrough' cancer drug

A new oncology compound from AbbVie and Roche's Genentech division cleared its primary hurdle in a Phase II blood cancer trial, opening the door to an FDA filing by year's end.